Anushua Sinha1, Louise B Russell, Sara Tomczyk, Jennifer R Verani, Stephanie J Schrag, James A Berkley, Musa Mohammed, Betuel Sigauque, Sun-Young Kim. 1. From the *Department of Health Systems and Policy, Rutgers School of Public Health, Newark, New Jersey; †Institute for Health, Health Care Policy, and Aging Research, Rutgers - The State University of New Jersey, New Brunswick, New Jersey; ‡Division of Bacterial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; §KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya & Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, United Kingdom; ¶College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia; ‖Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique; and **Division of Management, Policy and Community Health University of Texas School of Public Health, San Antonio, Texas.
Abstract
BACKGROUND: Group B streptococcus (GBS) is a leading neonatal sepsis pathogen globally. Investment in GBS disease prevention, such as maternal vaccination, requires evidence of disease burden, particularly in high infant mortality regions like sub-Saharan Africa. We aimed to provide such evidence by conducting a systematic literature review and meta-analysis to estimate maternal colonization proportion, GBS disease incidence and GBS serotype distribution. METHODS: MEDLINE, MEDLINE in process and Cochrane Library were searched for studies published during 1990-2014, pertaining to sub-Saharan Africa. Eligible studies were used to estimate the proportion of pregnant women colonized with GBS, early-onset GBS disease incidence, late-onset GBS disease incidence and respective serotype distributions. Random effects meta-analysis was conducted to estimate weighted means and confidence intervals (CIs). RESULTS: We identified 17 studies of colonization, 9 of disease incidence, and 6 of serotype distribution meeting inclusion criteria. 21.8% (95% CI: 18.3, 25.5) of expectant women were colonized with GBS. The incidence of early-onset GBS disease was 1.3 per 1000 births (95% CI: 0.81, 1.9), that of late-onset GBS disease 0.73 per 1000 births (95% CI: 0.48, 1.0). The most common disease-causing serotype was 3, followed by 1a. Serotypes 1b, 2 and 5 were next most common in frequency. CONCLUSION: Despite methodological factors leading to underestimation, GBS disease incidence appears high in sub-Saharan Africa. A small number of GBS serotypes cause almost all disease. GBS disease burden in sub-Saharan Africa suggests that safe, effective and affordable GBS disease prevention is needed.
BACKGROUND:Group B streptococcus (GBS) is a leading neonatal sepsis pathogen globally. Investment in GBS disease prevention, such as maternal vaccination, requires evidence of disease burden, particularly in high infant mortality regions like sub-Saharan Africa. We aimed to provide such evidence by conducting a systematic literature review and meta-analysis to estimate maternal colonization proportion, GBS disease incidence and GBS serotype distribution. METHODS: MEDLINE, MEDLINE in process and Cochrane Library were searched for studies published during 1990-2014, pertaining to sub-Saharan Africa. Eligible studies were used to estimate the proportion of pregnant women colonized with GBS, early-onset GBS disease incidence, late-onset GBS disease incidence and respective serotype distributions. Random effects meta-analysis was conducted to estimate weighted means and confidence intervals (CIs). RESULTS: We identified 17 studies of colonization, 9 of disease incidence, and 6 of serotype distribution meeting inclusion criteria. 21.8% (95% CI: 18.3, 25.5) of expectant women were colonized with GBS. The incidence of early-onset GBS disease was 1.3 per 1000 births (95% CI: 0.81, 1.9), that of late-onset GBS disease 0.73 per 1000 births (95% CI: 0.48, 1.0). The most common disease-causing serotype was 3, followed by 1a. Serotypes 1b, 2 and 5 were next most common in frequency. CONCLUSION: Despite methodological factors leading to underestimation, GBS disease incidence appears high in sub-Saharan Africa. A small number of GBS serotypes cause almost all disease. GBS disease burden in sub-Saharan Africa suggests that safe, effective and affordable GBS disease prevention is needed.
Authors: J Milledge; J C J Calis; S M Graham; A Phiri; L K Wilson; D Soko; M Mbvwinji; A L Walsh; S R Rogerson; M E Molyneux; E M Molyneux Journal: Ann Trop Paediatr Date: 2005-06
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: BMJ Date: 2009-07-21
Authors: Sun-Young Kim; Louise B Russell; Jeehyun Park; Jennifer R Verani; Shabir A Madhi; Clare L Cutland; Stephanie J Schrag; Anushua Sinha Journal: Vaccine Date: 2014-02-11 Impact factor: 3.641
Authors: Samir K Saha; Zabed B Ahmed; Joyanta K Modak; Hakka Naziat; Shampa Saha; Mohammad A Uddin; Maksuda Islam; Abdullah H Baqui; Gary L Darmstadt; Stephanie J Schrag Journal: J Clin Microbiol Date: 2017-05-17 Impact factor: 5.948
Authors: A Roca; A Bojang; B Camara; C Oluwalana; K Lette; P West; U D'Alessandro; C Bottomley Journal: Clin Microbiol Infect Date: 2017-05-03 Impact factor: 8.067
Authors: Louise B Russell; Sun-Young Kim; Ben Cosgriff; Sri Ram Pentakota; Stephanie J Schrag; Ajoke Sobanjo-Ter Meulen; Jennifer R Verani; Anushua Sinha Journal: Vaccine Date: 2017-11-10 Impact factor: 3.641
Authors: Lola Madrid; Anna C Seale; Maya Kohli-Lynch; Karen M Edmond; Joy E Lawn; Paul T Heath; Shabir A Madhi; Carol J Baker; Linda Bartlett; Clare Cutland; Michael G Gravett; Margaret Ip; Kirsty Le Doare; Craig E Rubens; Samir K Saha; Ajoke Sobanjo-Ter Meulen; Johan Vekemans; Stephanie Schrag Journal: Clin Infect Dis Date: 2017-11-06 Impact factor: 20.999